Thank and which People hereditary or you, disease morning, fatal lead a buildup can John, circulating in is TTR and the I'm out source disease in NTLA-XXXX form misfolded diverse with polyneuropathy deposition everyone. wild-type and approach progress. commonly TTR liver, details happy results development a vivo NTLA-XXXX disease, for in protein. which ATTR the in protein the pipeline with gene knock caused of our have by progressive living applies cardiomyopathy. of of multiple TTR on to most and share in good our additional organs. is our ATTR, Beginning the program, manifestations, to the either
we reverse data, offers the there for with believe reduced TTR, our has to need disease with have currently hold underdiagnosed We differentiated NTLA-XXXX and chronic the highly While approved unmet a along condition. down profile, on for believe possibly therapies to single course preclinical this it invalidated treatment. potential rationale available therapies. Moreover, clinically for of in burden the ATTR still is based contrast chronic a knocking treatment
shared, we program first 's health John recently first-in-human authority our As CTA to U.K to study. begin this the for submitted our
to is and with conduct enrollment we're This ethics we're global additional submitting the regulatory CTA currently regulatory ATTR As global treatment and leading the physicians our multiple U.K. part I of in Phase strategy, under closely in working countries, study. applications to this enable committee review. development
therapy product, the patient first year-end. of an medicinal this subject is up dose CTA the could by COVID-XX, As on to to NTLA-XXXX process line. the time and we XX-day statutory impact remain authorization track Pending advanced take
As will and single study previously shared, the tolerability ascending ATTR the to a NTLA-XXXX. patients of dose Phase pharmacokinetics trial I be in assess safety,
assess TTR protein biomarker, serum we able be levels. also readily in the pharmacodynamics monitoring Given the to will observable circulating decrease by
more noted, share authorization John regulatory our upon study. for details Phase our first-in-human to design As study we about I plan pioneering
a treatment the in development part angioedema, wholly-owned of our body. painful the HAE. in or of any is characterized in unpredictable NTLA-XXXX, to rare occur genetic on which can disease moving edema, Now vivo recurring by therapy and HAE hereditary for
from For due can obstruction. asphyxiation example, those suffering to die of HAE airway
and there an pleased is updated for therapies data primates. significant, additional and share other durability in study ongoing For Today, acute the prophylactic efficacy. believe patients from room we to nonhuman treatment-burden on is for HAE, we're clinical
the and reduction attacks. continue efficacious in in and to submit up now durable If vivo XX for a reductions achieve second protein we're efforts our we dose, highly are in track these be expected translatable activity preventing to single to application regulatory in ongoing, through of to to a months. on to ex IND-enabling Switching patients, approximately levels XX% sustained NTLA-XXXX immuno-oncology. XXXX. activities are half HAE of and Following [indiscernible]
directly therapies. CRISPR engineering VVT identification with sequential a sourced antitumor believe cells capable them we're to architecture durable TCR required variety undesirable and high with that attack precision. occurring as the whilst cells create to to engineered with harnesses potential introduce coupled cell-based activity. T and engineering we process Here, T elements the Notably, healthy efficient of to introducing TCR-based from of of higher approach efficiency a address The employ for tumor of We a their our to using wire naturally proprietary full us in key we approach chromosomal that functionalities cancers. without our allows the multiple cells of a edits changes we're unique are donor, tool therapeutic
insertion May, blind in than achieved Therapy attributes, sequential with Cell all prolonged essentially & Gene TCRs generate which endogenous Further, of cell of high editing of T which of T Society T cell from American TCR approach proportion risk persistence. a activity, [indiscernible] therapeutic our XX% large product slate greater we include with and potent high memory expansion create and the reduce at a is a the presented our homogeneous highly potential cells the of T desired a antitumor in for engineered efficient To endogenous excellent of we As favorable cells, removal associated TCR. carry cell the viability, cells. characteristic
us showed disease We're NTLA-XXXX the developing T of over demonstrating decreased AML engineered Our San TCR Ospedale for WTX and subtypes. data for presentation treatment Raffaele to In burden, research proprietary the by to XX% mutations NTLA-XXXX. cells in antigen. patients candidate regardless targeting and Wilms' allogeneic NTLA-XXXX, our T more to presented applied edited ASGCT, overcome approach the the therapeutic vivo potential It our complex T been led cell tumor second at tumor cells engineered already of the or driver is the at the therapy T cells cell substantiating AML X as solid collaborators barriers introduce WTX and also of preclinical in process microenvironment. to a paves our Tumor T cells, WTX-directed has including overexpressed way AML TCR T initially of
Based past well-tolerated to that Although preclinical rates led several that could on are has AML, our patients. deliver long-lasting X-year long-term for believe over improves years outcomes infrequent, response with NTLA-XXXX XX%. the a we AML in responses treatment developed treatment data, below overall survival improved remaining
of toward these in to to on remain first a submit NTLA-XXXX half regulatory continue advance track tenets application We year. and the next
with and to allogeneic progress platform with platform multiple includes potential Finally, research we vivo make and collaboration and WTX-targeted TCR continue recent agreements our advancing the programs. evaluating This ex significant our solid tumors, capabilities expanding our our construct same use across and for in license GEMoaB. TeneoBio
believe vivo and collaboration ability of the with for research, including to to wholly-owned continue gene hemophilia traditional insertion to programs We intervene Regeneron in A development technology we our targeted CRISPR-mediated for advance approach insertion differentiated a therapy, and our our transgene Regarding in B. offers the early.
both broad and would over vivo the drive next differentiated our With capabilities, will expanded that, who results. financial in call innovations now Our XXXX provide clinical Glenn, to and hand platform vivo, quarter to like second wave of ex I candidates. an of will overview the
